FDA OKs Sanofi Sarclisa combo for relapsed or refractory multiple myeloma

 

• Sarclisa regimen reduced risk of disease progression or death by 45% compared to standard of care in patients who had relapsed after one to three prior therapies

• While the median progression free survival (PFS) for Sarclisa combination therapy is not yet reached, consistent improvement in PFS is seen across patient subgroups

• This is the second FDA approval for Sarclisa in combination with standard of care backbone therapies

https://finance.yahoo.com/news/fda-approves-sarclisa-isatuximab-combination-211500039.html